Cargando…
Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial
The macrolide clarithromycin has been reported as active for therapy of mucosa associated lymphoid tissue (MALT) lymphoma. Pharmacokinetic properties, however, require continuous daily intake over a prolonged period of time. As the macrolide azithromycin is characterized by a long half‐life as well...
Autores principales: | Lagler, Heimo, Kiesewetter, Barbara, Dolak, Werner, Obermueller, Markus, Simonitsch‐Klupp, Ingrid, Lukas, Julius, Neuper, Ortrun, Lamm, Wolfgang W., Mayerhoefer, Marius E., Raderer, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585850/ https://www.ncbi.nlm.nih.gov/pubmed/30153341 http://dx.doi.org/10.1002/hon.2555 |
Ejemplares similares
-
Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2019) -
Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
por: Kiesewetter, Barbara, et al.
Publicado: (2020) -
Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma
por: Scheibenpflug, Raphael, et al.
Publicado: (2021) -
First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2020) -
Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients
por: Kiesewetter, Barbara, et al.
Publicado: (2014)